Fluorescence in situ hybridization has become an essential detection assay in today´s routine diagnostics. However, long hybridization times of many hours to overnight are still a restrictive factor. We have refined the production process of our FISH probes to reduce background and artefacts and to improve the signal to noise ratio, particularly in short-time hybridization. Since mid-2015, one hour hybridization on lymphocytes is an integral part of quality control for all XCyting locus-specific probes at our manufacturing facility.
XL 19p/19q del
- Order Number
- Package Size
- 100 µl
XL 19p/19q del detects deletions in the long arm of chromosome 19. The orange labeled probe hybridizes to the GLTSCR1 and GLTSCR2 locus at 19q13. A green labeled probe hybridizes to a specific locus at 19p13 and functions as a reference probe.
This probe is intended for methanol/acetic-acid fixed cells and tissue sections.
The 2016 ´World Health Organization Classification of Tumors of the Central Nervous System´(WHO 2016) combines, for the first time, histological features and molecular signatures for the definition of many tumor entities. Gliomas are a category of tumors of the brain and spinal cord starting in glia cells. Oligodendrogliomas are a subtype of gliomas accounting for up to 18% of all cases. According to the WHO 2016, the classification of an oligodendroglioma requires information about the isocitrate dehydrogenase mutation status and 1p/19q loss of heterozygosity (LOH). LOH of 19q can be detected in about 80% of oligodendroglial tumors and to a lower extend in mixed gliomas. Co-deletion of 1p/19q is a well-accepted prognostic biomarker in neuro-oncology. Patients suffering from anaplastic oligodendroglioma harboring 1p/19q deletion, generally have a good prognosis. Co-deletion of 1p/19q has also predictive character, the molecular status of 1p/19q is relevant for therapy decisions.
- Solid Tumors (Solid Tumors)
Two green (2G) and two orange (2O) signals.
Aberrant Cell (typical results):
Two green (2G) and one orange (1O) signal resulting from loss of one orange signal.
- Reifenberger et al (1994) Am J Pathol 145:1175-1190
- Louis et al (2016) Acta Neuropathol 131:803-820
- Staedtke et al (2016) Trends Cancer 2:338-349